Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destruction.

ABSTRACT:

Introduction

Breast cancer-related bone metastasis can lead to skeletal-related events (SREs), which decrease patient quality of life. Inhibition of osteoclastogenesis is a key treatment for SREs; however, the availability of clinical drugs remains limited, and all existing ones disrupt physiological bone formation, while exhibiting no effect on patient survival time.

Objectives

This study aimed to identify a novel osteoclast inhibitor for the treatment of breast cancer-induced SREs.

Methods

The MDA-MB-231 breast cancer cell-induced bone loss model was used to investigate the therapeutic effects of erianin in vivo. Then, we evaluated the inhibitory effects of erianin on osteoclastogenesis and signalling in bone marrow-derived macrophages (BMMs) induced by conditioned

SUBMITTER: Zheng J 

PROVIDER: S-EPMC11954832 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature